NUVL - Meet members of the 2021 IPO class: oncology-focused biotechs

A record 62 recent IPOs joined the Russell 2000 small-cap index this month. Here's a look at some of the biotech stocks that just joined: Lyell Immunopharma Lyell Immunopharma (NASDAQ:LYEL), which is developing T cell therapies for solid tumors, had a 25M-share IPO in June expected to net proceeds of ~$425M. All of the companies candidates are in the preclinical stage. Its TCR t cell product candidate, for synovial sarcoma and other solid tumors, is in partnership with GlaxoSmithKline. Erasca Erasca (NASDAQ:ERAS) is focused on RAS/MAPK pathway-driven cancers. It had an 18.75M-share IPO in July that led to gross proceeds of $345M. The company's lead candidate, ERAS-007, is in phase 2 for solid tumors, non-small cell lung cancer ("NSCLC"), and colorectal cancer. Nuvalent Nuvalent (NASDAQ:NUVL) is a preclinical oncology biotech. Its ~11.2M-share IPO that closed in early August had gross proceeds of $190.6M. Its lead candidate, NVL-520, is in IND-enabling

For further details see:

Meet members of the 2021 IPO class: oncology-focused biotechs